Cyclooxygenase-2 Inhibitors Attenuate Angiotensin II–Induced Oxidative Stress, Hypertension, and Cardiac Hypertrophy in Rats
- 1 June 2005
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hypertension
- Vol. 45 (6), 1139-1144
- https://doi.org/10.1161/01.hyp.0000164572.92049.29
Abstract
Angiotensin II is an important oxidative stress mediator. Our previous studies have indicated that the potent antioxidative properties of acetylsalicylic acid play an important role in its cardiovascular protective effects. There are some ongoing controversies concerning the use of selective cyclooxygenase-2 inhibitors in cardiovascular disease. The aim of this study was to determine whether the cyclooxygenase-2 selective inhibitors rofecoxib and nimesulide possess antioxidative and cardiovascular protective effects against angiotensin II. Chronic subcutaneous angiotensin II infusion increased cardiovascular but not colonic tissue superoxide production, heart/body weight ratio, and blood pressure. Moreover, angiotensin II selectively increased cardiac cyclooxygenase-2 but not cyclooxygenase-1 expression, which was totally prevented by acetylsalicylic acid treatment. Similar to acetylsalicylic acid, rofecoxib or nimesulide treatments significantly attenuated angiotensin II–induced oxidative stress, hypertension, and cardiac NAD(P)H oxidase subunit p47 phox expression. Rofecoxib also reduced cardiac hypertrophy. Treatment with nonselective anti-inflammatory drugs ibuprofen, indomethacin, or salicylic acid did not show any effect on angiotensin II–induced superoxide production, hypertension, or cardiac hypertrophy. Although acetylsalicylic acid and salicylic acid inhibited angiotensin II–induced nuclear factor κB (NF-κB) activation, nimesulide did not modify NF-κB activation. In conclusion, cyclooxygenase-2 pathway is implicated in angiotensin II–induced oxidative stress and deleterious cardiovascular changes. Rofecoxib and nimesulide produced significant antioxidative effect by reducing NAD(P)H oxidase–dependent superoxide generation. These effects seem to be independent of NF-κB inhibition.Keywords
This publication has 19 references indexed in Scilit:
- Prevention of angiotensin II-induced hypertension, cardiovascular hypertrophy and oxidative stress by acetylsalicylic acid in ratsJournal Of Hypertension, 2004
- Differential Effects of Selective Cyclooxygenase-2 Inhibitors on Endothelial Function in Salt-Induced HypertensionCirculation, 2003
- NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophyJournal of Molecular and Cellular Cardiology, 2003
- Role of oxidative stress in angiotensin-induced hypertensionAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2003
- Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritisThe American Journal of Cardiology, 2002
- The Coxibs, Selective Inhibitors of Cyclooxygenase-2New England Journal of Medicine, 2001
- Angiotensin II activates nuclear transcription factor‐κB in aorta of normal rats and in vascular smooth muscle cells of AT1 knockout miceNephrology Dialysis Transplantation, 2001
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Inhibition by cyclic AMP of basal and induced inositol phosphate production in cultured aortic smooth muscle cells from Wistar- Kyoto and spontaneously hypertensive ratsJournal Of Hypertension, 1996
- Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B.Proceedings of the National Academy of Sciences of the United States of America, 1989